# DYNA TERBUTALINE SYRUP

MAL19910178AZ

**DESCRIPTION:**
SYRUP
Colour : Colourless
Flavour : Pineapple

**CONTENT:**
Each 5 ml contains:
Terbutaline Sulphate..... 1.5 mg
Preservatives: Methyl Paraben 0.1% w/v & Propyl Paraben 0.01% w/v.

**PHARMACODYNAMICS:**
Terbutaline Sulphate is a directly acting sympathomimetic amine with bronchodilator actions. It acts on the adrenergic receptors in the bronchi and the respiratory tract.

**PHARMACOKINETICS**
Terbutaline Sulphate is partially absorbed after oral administration. After an oral dose of 5 mg of Terbutaline Sulphate, peak serum concentrations of about 3 to 6 ng/ml are attained in 1 to 3 hours. The serum half-life is 3 to 4 hours. Small amount of the drug is secreted in the milk. Terbutaline Sulphate is subjected to first pass metabolism mainly by Sulphate conjugation; glucuronic acid conjugates are formed to some extent but the drug does not appear to be methylated. After an oral dose, up to about 50% is excreted in the urine, mostly as the Sulphate.

**INDICATION:**
In the treatment of asthma, chronic bronchitis, emphysema and other bronchopulmonary disorders involving bronchospasm.

**RECOMMENDED DOSE:**
Adults : 2 to 3 teaspoonfuls (10 ml to 15 ml).
Children : under 3 years : ½ teaspoonful (2.5 ml).
3 to 5 years : ½ to 1 teaspoonful (2.5 ml to 5 ml).
6 to 12 years : 1 to 2 teaspoonfuls (5 ml to 10 ml).
To be given 3 times daily.

**CONTRAINDICATION:**
It is contraindicated in patients with hypertension, myocardial insufficiency and hyperthyroidism.

**WARNING AND PRECAUTIONS:**
It should not be administered with non-selective beta-adrenoreceptor blocking drugs such as Propranolol or Oxprenolol.
Tocolysis: Serious adverse reactions including death have been reported after administration of Terbutaline to women in labor. In the mother, these include increased heart rate, transient hyperglycaemia, hypokalaemia, cardiac arrhythmias, pulmonary oedema and myocardial ischaemia. Increase fetal heart rate and neonatal hypoglycaemia may occur as a result of maternal administration.

**DRUG INTERACTION:**
Beta-blocking agents (including eye drops), especially the non-selective ones such as Propranolol, may partially or totally inhibit the effect of β-stimulants. Therefore Terbutaline and non-selective β-blockers should not normally be administered concurrently.
Terbutaline should be used with caution in patients receiving other sympathomimetics.
There is an increased the risk of hypokalaemia if high doses of Terbutaline is given concomitantly with corticosteroids, diuretics (acetazolamide, loop diuretics, and thiazides) or Theophylline.

**PREGNANCY AND LACTATION:**
Risk and benefit should be considered when used during pregnancy. The amount excreted in breast milk is too small to be harmful.

**SIDE EFFECTS/ADVERSE REACTIONS:**
Palpitation, tachycardia, muscle tremors, increase in blood pressure and severe headache.

**SYMPTOMS AND TREATMENT OF OVERDOSE**
Symptoms of overdosage include muscle tremor, flushing, agitation, palpitations, sinus tachycardia and hypokalemia. Treatments include gastric lavage or emesis and the use of beta-adrenoreseptor blocking agents, usually Propranolol.

**PACKING/PACK SIZE(S):**
Plastic bottles of 60 ml and 120 ml.

**JAUHI UBAT DARIPADA KANAK-KANAK**
**KEEP OUT OF REACH OF CHILDREN**
**SHAKE WELL BEFORE USE**

---

**MANUFACTURER/PRODUCT REGISTRATION HOLDER:**
**DYNAPHARM (M) SDN. BHD.** 198001011897 (65683-V)
2497, Mk. 1, Lorong Perusahaan Baru 5,
Kawasan Perusahaan Perai 3,
13600 Perai, Pulau Pinang, MALAYSIA

PI1PL D030-00
Latest Revision: Aug 2022